STAT· Andrew Joseph·· 4 hours agoPickScore40
STAT+: A German biotech has big ambitions in cancer. Now it needs to get a medicine approved
In brief
At a major European oncology conference, a German biotech presented Phase 1 data for its cell therapy in uveal melanoma, with tumors shrinking in all 16 patients. Oncologist Sapna Patel noted that the target could extend to solid tumors resistant to immunotherapy, such as pancreatic and ovarian cancer.
Why it matters
Phase 1 data show tumor shrinkage in all 16 uveal melanoma patients.
Source: STAT · statnews.com